Abstract
Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and thirdgeneration calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable “therapeutic cross effects” due to pleiotropic mechanisms can be defined as pleiosynergy.
Keywords: Statin, amlodipine, vascular effect, pleiotropic, synergy
Current Vascular Pharmacology
Title: Vascular Pleiosynergy - Does It Really Work?
Volume: 5 Issue: 4
Author(s): Albert Csaszar
Affiliation:
Keywords: Statin, amlodipine, vascular effect, pleiotropic, synergy
Abstract: Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and thirdgeneration calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable “therapeutic cross effects” due to pleiotropic mechanisms can be defined as pleiosynergy.
Export Options
About this article
Cite this article as:
Csaszar Albert, Vascular Pleiosynergy - Does It Really Work?, Current Vascular Pharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157016107782023352
DOI https://dx.doi.org/10.2174/157016107782023352 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies)
Current Pharmaceutical Design Autosomal Dominant Hypercholesterolemia: Needs for Early Diagnosis and Cascade Screening in the Tunisian Population
Current Genomics Atorvastatin-Loaded Oleic Acid Nanoglobules for Oral Administration: In Vitro Characterization and Biopharmaceutical Evaluation
Current Nanoscience Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders
Current Pharmaceutical Design Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling
Current Medicinal Chemistry Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition
Current Topics in Medicinal Chemistry Anti-Bacterial Drug Discovery Using Systems Biology
Mini-Reviews in Medicinal Chemistry Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets Hypertension: Quo Vadis?
Current Vascular Pharmacology Editorial [Hot topic:Vascular Protective Effects of Ezetimibe: Seeking New Therapeutic Possibilities of Ezetimibe in Vascular Disease (Guest Editor: Minako Yamaoka-Tojo)]
Current Vascular Pharmacology Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Natural Products as a Source of Antiarrhythmic Drugs
Mini-Reviews in Medicinal Chemistry New Horizons in Diabetes Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)